2021
Pacific Edge Announces Agreement with Northern Health in Australia
Pacific Edge is pleased to announce today that it has reached its first commercial agreement of scale in Australia with Northern Health, a major provider of healthcare and hospital services to Melbourne’s rapidly growing outer northern suburbs. [read more]
Cxbladder on the Podium at the Annual SUO Meeting in the US
Late last week, at the Annual Meeting of the Society of Urologic Oncology (SUO) in Orlando USA, urologists at UCSF presented their findings on the use of Cxbladder Monitor (CxbM) in a real-world setting for managing patients during COVID-19. [read more]
Pacific Edge Results For Six Months Ended 30 September 2021
Pacific Edge reports continued strong revenue growth despite continuing impact of Covid-19. [read more]
Interim Financial Result To Be Announced 25 November 2021
Pacific Edge advises that its half year results for the six months ending 30 September 2021 will be released on Thursday 25 November 2021, prior to 10am. [read more]
Pacific Edge Appoints Dr Peter Meintjes As Its New CEO
Pacific Edge appoints Dr Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer. [read more]
Pacific Edge Named In Deloitte Fast 50 Awards
Pacific Edge has once again been named in the Deloitte Fast 50 Awards, as it continues to execute on its commercial strategy and drive revenue growth. [read more]
Pacific Edge Retail Offer Closes Over Subscribed
Pacific Edge advises that its Retail Offer has closed oversubscribed. The Offer received very strong support from existing eligible shareholders with applications totalling NZ$80.0m, NZ$60.0m (300%) above the NZ$20m offered. [read more]
Pacific Edge Investor Newsletter - October 2021
Pacific Edge is pleased to present the latest edition of its regular Investor Newsletter. [read more]
Pacific Edge Retail Offering Closing Date Reminder
Pacific Edge would like to remind Eligible Shareholders of the opportunity to subscribe for new ordinary shares in Pacific Edge through the Retail Offer. The Retail Offer closes at 5.00pm NZDT on Wednesday 13 October 2021. [read more]
Pacific Edge Opens Retail Offer for Existing Shareholders
Pacific Edge has today opened its retail offer which forms part of the capital raising announced to the market on 23 September 2021. Eligible Shareholders in New Zealand are being offered the opportunity to participate in the Retail Offer, to raise up to a further NZ$20m (A$19.4m). [read more]
Pacific Edge Placement Upsized Following Strong Demand
Pacific Edge Limited is pleased to announce it has successfully raised NZ$80m (A$77.5m) through its Placement. The Placement was very well subscribed, resulting in Pacific Edge increasing the size of the Placement from NZ$60m (A$58.1m) to NZ$80m (A$77.5m). [read more]
PEB Dual Lists on ASX; Announces Capital Raise to Accelerate Execution of Growth Opportunities
Pacific Edge is pleased to announce that it has been admitted to the official list of the Australian Securities Exchange (ASX) as a foreign exempt listing and is conducting an equity raise to accelerate execution of growth opportunities. [read more]
PEB Applies For Australian Stock Exchange (ASX) Dual Listing
Pacific Edge Limited will today lodge an application with the Australian Stock Exchange (ASX) to dual list as a Foreign Exempt Entity. Subject to the ASX accepting the application, PEB expects to be dual-listed on the ASX by the end of September 2021. [read more]
Journal of Urology Publishes Outperformance of Cxbladder in US Covid-19 Setting
The American Urological Association’s (AUA) Journal of Urology has published a real world lookback highlighting the clinical utility of Cxbladder in a Covid-19 setting for the management of patients outside the clinic. [read more]
Taranaki District Health Board Adopts Full Suite of Cxbladder Tests
Pacific Edge is pleased to confirm that the company has reached commercial agreement with Taranaki District Health Board (DHB) for the use of Cxbladder products across the clinical pathway in the detection, management, and monitoring of bladder cancer patients. [read more]
Results from the Pacific Edge Annual Shareholder's Meeting
Results from Pacific Edge's annual shareholder meeting, held in Dunedin and online yesterday. Shareholders were asked to vote on 5 resolutions. [read more]
Pacific Edge Reports Continued Growth Momentum into Q1 FY22
Pacific Edge is pleased to report a continuation of the positive growth momentum seen in the second half of the prior financial year, with sales of our Cxbladder tests continuing their strong growth. [read more]
2021 Annual Shareholders Meeting Presentations & Speeches
View speeches by our Chairman and CEO along with the presentation for today's meeting [read more]
Combined Use of Cxbladder Products Shows Significant Outperformance
A pivotal, peer-reviewed paper, accepted for publication in the Journal of Urology, demonstrates the significant clinical and patient benefits from the use of a combination of Cxbladder products to correctly identify haematuria patients, who have urothelial cancer (UC) and also, further segregate those patients with high-impact tumours (HIT) requiring priority investigation. [read more]
Cxbladder Continues To Win Over NZ Public Healthcare Providers
Pacific Edge is pleased to advise that it has reached a commercial agreement with Northland District Health Board (DHB) and Northland’s primary health entity Mahitahi Hauora for the use of Cxbladder products. [read more]
Pacific Edge Annual Report & Review Letter 2021
Pacific Edge’s Annual Report for the year ended 31 March 2021 is now available to view. We invite you to read this, along with our Annual Review Letter. [read more]
Notice of Annual Shareholder Meeting
Pacific Edge advises that its 2021 Annual Shareholders’ Meeting will be held in the Fullwood Room, Dunedin Centre, 1 Harrop Street, Dunedin on Thursday 29 July 2021, commencing at 3.00pm. [read more]
Kaiser Permanente to Commence Commercial Use of Second Cxbladder Test
Pacific Edge is pleased to announce that it has been informed by Kaiser Permanente that it intends to commence the commercial use of a second Cxbladder product, Cxbladder Triage, from the beginning of July 2021. [read more]
Director Nomination Closing Date
Pacific Edge advises that its Annual Shareholder Meeting will be held on Thursday 29 July 2021, with Director nominations closing on 17 Jun. [read more]
Pacific Edge reports strong growth momentum despite COVID-19
Pacific Edge is pleased to present audited financial results for the 12 months to 31 March 2021. The company reports accelerating revenue growth in its key markets in FY21, despite the ongoing challenges of COVID-19 throughout the year. [read more]
Pacific Edge Wins Prestigious INFINZ Investor Relations Award
Pacific Edge has been named as the winner of the NZX Emerging Leaders Best Investor Relations Award, at the prestigious INFINZ Awards dinner in Auckland on Tuesday night. The Award was open to all companies outside of the NZX20. [read more]
Pacific Edge Appoints Chief Operating Officer
Pacific Edge is pleased to announce the appointment of Demi Stefanova as Chief Operating Officer, effective from 21 June 2021. [read more]
Pacific Edge Appoints Mark Green as Independent Director
Pacific Edge is pleased to welcome Mark Green as an Independent Director, effective from 10 May 2021. Mark is an experienced corporate finance professional, with approximately 25 years of experience in the Australasian capital, corporate and financial markets. [read more]
Pacific Edge Full Year Result to be Announced 27 May
Pacific Edge advises that its full year results for the 12 months to 31 March 2021 (FY21) will be released on Thursday 27 May 2021, prior to 10am. [read more]
Pacific Edge Appoints Chief of Information Systems and Decision Support
Pacific Edge is pleased to announce the appointment of Andrew McIntosh as Chief of Information Systems and Decision Support, effective from 1 June 2021. [read more]
Pacific Edge Named Finalist in INFINZ Awards
Pacific Edge is delighted to have been named as a finalist in the INFINZ Awards for Emerging Leaders Best Investor Relations. [read more]
Pacific Edge Investor Newsletter - April 2021
Pacific Edge is pleased to present the latest edition of its regular Investor Newsletter. [read more]
Pacific Edge CEO, David Darling, Announces Intention to Retire
Pacific Edge CEO, David Darling, has advised the company’s Board that he intends to retire from his role on 6 April 2022. Following this, David will continue to support the company in a consulting role. [read more]
United Healthcare Issues Positive Coverage Decision for Cxbladder
Pacific Edge is pleased to advise that its Cxbladder bladder cancer diagnostic tests are now covered by United Healthcare, the largest healthcare group in the US. [read more]
PEB Concludes Commercial Agreement With Facey Medical Group in US
Pacific Edge Limited has concluded a commercial agreement with Facey Medical Group, a physician owned medical group in California. The agreement covers the use of Cxbladder Detect and Cxbladder Monitor for Facey Medical Group patients. [read more]
Pacific Edge Appoints Anna Stove as Independent Director
Pacific Edge is pleased to welcome Anna Stove as an independent Director, effective from 15 March 2021. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.